Combination therapyInvestigationalInvestigational

Pembrolizumab + Nivolumab

How it works

Combination of pembrolizumab (blocks PD-1) and nivolumab (blocks PD-1), allowing immune cells to recognize and attack cancer cells more effectively.

Cancer types

Melanoma— All patients

Efficacy

In clinical trials, around 60% of patients achieved an objective response, with median overall survival of approximately 12.9 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.